JAC Advance Access originally published online on October 7, 2004
Journal of Antimicrobial Chemotherapy 2004 54(5):944-951; doi:10.1093/jac/dkh445
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.54 no.5 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved
In vitro activity of ertapenem against selected respiratory pathogens
Sezione di Microbiologia del Di.S.C.A.T., University of Genoa, Largo R.Benzi 10, 16132 Genoa, Italy
* Corresponding author. Tel: +39-010-3537655; Fax: +39-010-3537698; Email: anna.marchese{at}unige.it
Objectives: The in vitro activity of ertapenem was evaluated in comparison to 21 selected agents against a large collection of recently isolated respiratory tract pathogens including: 180 Streptococcus pneumoniae, 100 Streptococcus pyogenes, 70 Haemophilus influenzae, 70 Moraxella catarrhalis, 100 methicillin-susceptible Staphylococcus aureus and 30 Klebsiella pneumoniae. Additional in vitro tests (time–kill curves with ertapenem alone and in combination with four other agents) for S. pneumoniae were carried out.
Methods: MIC determinations and time–kill curves were carried out following the procedures suggested by the NCCLS.
Results: According to NCCLS susceptibility breakpoints, ertapenem was comparable to the most potent compounds tested for all pathogens studied. Ertapenem was 100% active against penicillin-susceptible and -intermediate S. pneumoniae and against 60% of penicillin-resistant strains. Time–kill tests at 4x MIC confirmed a pronounced bactericidal potency of ertapenem against these organisms. Interactions of ertapenem with several other agents against pneumococci resulted in clear synergic interactions (98.4%). Indifference was extremely rare and antagonism was not observed. All S. pyogenes strains tested were inhibited by ertapenem, irrespective of their macrolide resistance phenotypes. Ertapenem was also fully active against H. influenzae (100% susceptible) and M. catarrhalis (MIC90 0.015–0.03 mg/L) even when capable of synthesizing ß-lactamases. Methicillin-susceptible S. aureus and K. pneumoniae, including extended-spectrum ß-lactamase-producing strains, were 100% susceptible to ertapenem.
Conclusions: Our results indicate that ertapenem has a suitable spectrum of activity against organisms encountered in community-acquired bacterial respiratory tract infections.
Keywords: carbapenems , time–kill , interactions , bactericidal activity , Streptococcus pneumoniae
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. G. Zhanel, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model J. Antimicrob. Chemother., January 1, 2007; 59(1): 144 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Decousser, I. Methlouthi, P. Pina, P. Allouch, and on behalf of The ColBVH Study In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains J. Antimicrob. Chemother., March 1, 2005; 55(3): 396 - 398. [Full Text] [PDF]
|
|